Taltz carries a list price of roughly $7,450 per single-dose autoinjector, and most treatment schedules require multiple doses per year, pushing the annual sticker price well above $20,000. Several forces converge to make it that expensive: the biology behind the drug, the manufacturing process, patent protection, and a pricing system built on hidden negotiations between drugmakers and insurance middlemen.
What Makes Biologics Costly to Produce
Taltz (ixekizumab) is a biologic, not a traditional pill. Traditional drugs are small molecules assembled through relatively straightforward chemical reactions. Biologics are large, complex proteins grown inside living mammalian cells that have been genetically engineered to produce them. Those cells also generate a messy mix of other proteins, DNA fragments, and cellular debris that all has to be separated out before the drug is safe to inject.
That purification process is one of the biggest cost drivers. A key step called affinity chromatography uses specially designed columns packed with synthetic proteins that grab onto the antibody molecules while everything else gets washed away. A single one of these columns can cost more than $10 million, according to researchers at Penn State who study ways to bring antibody therapy costs down. Multiply that across an entire production facility, add in the sterile environments, cold-chain shipping, and quality testing required for every batch, and the per-unit cost dwarfs what it takes to press a chemical pill into a tablet.
Patent Protection Blocks Cheaper Alternatives
When a traditional drug loses patent protection, generic manufacturers can produce near-identical copies and drive the price down quickly. Biologics work differently. Even after patents expire, competitors can only make “biosimilars,” which are close but not exact copies, and getting one approved requires expensive clinical trials to prove it performs the same way in the body.
For Taltz, that competition isn’t arriving anytime soon. The longest-filed patent on ixekizumab doesn’t expire until March 2033. No biosimilar for Taltz has been approved in the U.S. or Canada. Until that patent window closes and biosimilar manufacturers invest in development, Eli Lilly faces no direct price competition on the molecule itself. That exclusivity gives the company broad pricing power.
A few older biologics used for psoriasis, like adalimumab (Humira), etanercept (Enbrel), and infliximab (Remicade), do have biosimilar versions on the market. But those biosimilars took years to arrive after patent expiration, and their price reductions have been more modest than what you typically see with generic pills.
How Taltz Compares to Competitors
Taltz isn’t the only high-priced biologic in its class, but it sits at the upper end. Comparing list prices without insurance on Drugs.com, a course of Taltz (three autoinjectors) runs about $22,350, while a comparable quantity of Skyrizi comes in around $10,650. These are sticker prices before insurance negotiations, but the gap illustrates that even within the same disease category, pricing varies significantly.
All of these drugs target specific parts of the immune system to treat conditions like plaque psoriasis and psoriatic arthritis. They compete for the same patients, which in theory should push prices down. In practice, the competition plays out mostly through behind-the-scenes rebates rather than visible price cuts.
The Hidden Rebate System
The price you see listed for Taltz is not what your insurer actually pays. Between the manufacturer and the pharmacy counter sits a layer of companies called pharmacy benefit managers, or PBMs. These middlemen negotiate confidential discounts with drugmakers in exchange for placing a drug on a more favorable spot on insurance formularies (the lists that determine which drugs are covered and at what cost to you).
Manufacturers like Lilly set a high list price in part because they know they’ll be handing back a significant chunk as rebates. Research published in Health Affairs has shown that when new competitors enter a drug class, PBMs leverage that competition to negotiate steeper confidential discounts, lowering the “net price” insurers actually pay. But the list price often stays the same or even climbs, which matters because patients without insurance, or those with high-deductible plans, may get stuck paying based on that inflated sticker number.
This system means the true cost of Taltz is lower than $7,450 per dose for most insured patients’ plans, but the exact net price is confidential. If you’re uninsured or in a coverage gap, the list price is what hits your wallet.
What Patients Actually Pay
Eli Lilly runs a patient support program that can dramatically reduce out-of-pocket costs for people with commercial insurance. Eligible patients with insurance that covers Taltz can pay as little as $5 per month. Those with commercial insurance that doesn’t cover Taltz can access it for $25 per month. The savings card lasts up to 24 months and covers up to three pens per 28-day period, with monthly and annual spending caps.
There are limits. People on government insurance, including Medicare and Medicaid, don’t qualify for the copay program. For those patients, the options are more limited and often involve applying for separate patient assistance programs through the manufacturer or third-party foundations.
If you’re comparing biologic options partly on cost, it’s worth asking your insurance plan what your specific copay or coinsurance would be for Taltz versus alternatives like Skyrizi or Cosentyx. The list price differences between these drugs often shrink or even reverse once insurance negotiations and copay programs are factored in. Your pharmacist or specialty pharmacy can usually run a benefits check before you commit to a prescription.
Why the Price Isn’t Likely to Drop Soon
With patent protection running through 2033, no biosimilar competition on the horizon, and a rebate system that keeps list prices high even when net prices fall, Taltz’s price tag is unlikely to change meaningfully in the next several years. The manufacturing costs for biologics remain inherently higher than for traditional drugs, and the U.S. pricing system gives manufacturers little incentive to lower list prices when rebates and copay cards can shield most insured patients from the full number.
For patients, the practical takeaway is that the sticker price rarely reflects what you’ll actually owe, but navigating the gap between the two requires checking your specific insurance formulary and enrolling in available savings programs before filling a prescription.